Hims & Hers Health stock
HIMSNYSEHims & Hers Health, Inc., HealthcareISIN US4330001060
35Score 35 out of 100, Weak
Price and trend
41 / 100
Price history
−49% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 26% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 32).
The price is 51% below its 52-week high. Largest decline in 7 years: 87% (February 2021 to May 2022).
Chart figures for advanced users
- SMA 50$27.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)32
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.52
- The lowest closing price of the last twelve months.
- Resistance$40.02
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Hims & Hers Health, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $4.44B, is number 19 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.35B (up 59% year on year) and earnings of $128.37M (up 1.8%).
- For fiscal 2026, analysts expect on average revenue of $3.16B (up 34.5%) and adjusted earnings per share of −$0.85.
Show more
- MEQIRI Score 35 out of 100 (Weak): rank 610 of 702 in Healthcare, median 53.
- Our model puts fair value at $20.77, with the price 5% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 73.6% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 70
- High return on capitalReturn on invested capital 16.6% in fiscal 2025, Medical (Care Facilities) median 6.1%.
Weaknesses
- High debtDebt 4.39 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 37
- Loss-makingLoss of $190.84M over the last 12 months.Fundamentals 18
- Volatile share priceVolatility 93% a year over the last 12 months.Stability 37
Its standout strength is growth, while fundamentals and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $13.85 and expensive above $41.54 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $16.98, at 7.8% it would be $26.46.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 29.8% on the twelve months before. Revenue has grown strongly since 2019, at around 75% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating 4%, net 5%. Last 12 months: net −7%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 22 Feb 2027in 101 days
- Last reported
- 9 Nov 2026EPS reported −$0.14 (expected $0.06)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 85.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.85−43.6%
- Revenue
- $3.16B−1.5%
- Earnings per share
- $0.04−85.7%
- Revenue
- $3.9B−3.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −26.4%Hims & Hers lowered its 2026 adjusted EBITDA guidance and narrowed 2026 revenue growth to 33% to 34%, while raising its international revenue outlook.
“For the full year, we are tightening our 2026 revenue outlook to $3.13 billion to $3.15 billion, representing a year-over-year increase of 33% to 34%. We are reducing our 2026 adjusted EBITDA guidance range to between $257 million to $277 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 9 Nov 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $1.17M in total. 7 insiders sold, $9.88M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Boughton SoleilSale
28 Oct 2026, Chief Legal Officer
- Shares
- 3,462
- Price
- $27.60
- Value
- $95,551
- Boughton SoleilSale
14 Oct 2026, Chief Legal Officer
- Shares
- 3,461
- Price
- $29.06
- Value
- $100,577
- Okupe OluyemiSale
1 Oct 2026, Chief Financial Officer
- Shares
- 2,000
- Price
- $29.70
- Value
- $59,400
Show 22 more
- Boughton SoleilSale
30 Sept 2026, Chief Legal Officer
- Shares
- 3,461
- Price
- $29.17
- Value
- $100,957
- Okupe OluyemiSale
22 Sept 2026, Chief Financial Officer
- Shares
- 29,277
- Price
- $29.95
- Value
- $876,846
- Okupe OluyemiSale
17 Sept 2026, Chief Financial Officer
- Shares
- 12,313
- Price
- $28.82
- Value
- $354,861
- Boughton SoleilSale
16 Sept 2026, Chief Legal Officer
- Shares
- 6,236
- Price
- $27.86
- Value
- $173,735
- Chi MichaelSale
15 Sept 2026, Chief Operating Officer
- Shares
- 14,027
- Price
- $28.39
- Value
- $398,227
- Elshenawy MohamedSale
15 Sept 2026, CTO
- Shares
- 7,954
- Price
- $28.39
- Value
- $225,814
- Boughton SoleilSale
2 Sept 2026, Chief Legal Officer
- Shares
- 3,458
- Price
- $28.33
- Value
- $97,965
- Okupe OluyemiSale
19 Aug 2026, Chief Financial Officer
- Shares
- 4,938
- Price
- $29.99
- Value
- $148,111
- Boughton SoleilSale
19 Aug 2026, Chief Legal Officer
- Shares
- 25,111
- Price
- $27.55
- Value
- $691,808
- Autor Deborah M.Sale
18 Aug 2026, Chief Policy Officer
- Shares
- 16,773
- Price
- $27.85
- Value
- $467,128
- Okupe OluyemiSale
17 Aug 2026, Chief Financial Officer
- Shares
- 9,388
- Price
- $27.89
- Value
- $261,802
- Okupe OluyemiSale
17 Jul 2026, Chief Financial Officer
- Shares
- 7,163
- Price
- $31.99
- Value
- $229,168
- Okupe OluyemiSale
6 Jul 2026, Chief Financial Officer
- Shares
- 7,163
- Price
- $36.49
- Value
- $261,351
- Okupe OluyemiSale
22 Jun 2026, Chief Financial Officer
- Shares
- 18,197
- Price
- $34.03
- Value
- $619,217
- Okupe OluyemiSale
18 Jun 2026, Chief Financial Officer
- Shares
- 55,383
- Price
- $35.09
- Value
- $1.94M
- Carroll Patrick HarrisonSale
18 Jun 2026, Chief Medical Officer
- Shares
- 23,726
- Price
- $35.00
- Value
- $830,410
- Chi MichaelSale
17 Jun 2026, Chief Operating Officer
- Shares
- 14,027
- Price
- $31.50
- Value
- $441,851
- Becklund IreneSale
17 Jun 2026, PAO
- Shares
- 4,490
- Price
- $31.50
- Value
- $141,435
- Elshenawy MohamedSale
17 Jun 2026, CTO
- Shares
- 30,040
- Price
- $31.50
- Value
- $946,260
- Becklund IreneSale
16 Jun 2026, PAO
- Shares
- 7,573
- Price
- $30.25
- Value
- $229,083
- Wells David BPurchase
26 May 2026, Board
- Shares
- 48,400
- Price
- $24.24
- Value
- $1.17M
- Okupe OluyemiSale
18 May 2026, Chief Financial Officer
- Shares
- 7,950
- Price
- $23.64
- Value
- $187,916
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Hims & Hers Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Fortis HealthcareFORTIS.NS $6.1B52
- Concentra Group Holdings ParentCON $5.44B69
- LifeStance Health GroupLFST $5.38B57
- Option Care HealthOPCH $4.75B64
- MedicoverMCOV-B.ST $4.01B61
- Acadia HealthcareACHC $3.52B48
- Surgery PartnersSGRY $3.48B53
- National HealthCareNHC $3.3B68
ETFs that hold Hims & Hers Health
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.40% | 0.68% | €5.31M |
| iShares Ageing Population UCITS ETF2B77 | 0.44% | 0.40% | €813.42M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.16% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.15% | 0.30% | €5.36B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.14% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.08% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.